Shopping Cart
- Remove All
- Your shopping cart is currently empty
Mupadolimab (CPI-006) is a humanized FC-γR binding deficient IgG1 anti-CD73 antibody with potential anticancer activity and activation of CD73POS B cells.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $222 | In Stock | |
5 mg | $463 | In Stock | |
10 mg | $878 | In Stock | |
25 mg | $1,280 | In Stock | |
50 mg | $1,760 | In Stock |
Description | Mupadolimab (CPI-006) is a humanized FC-γR binding deficient IgG1 anti-CD73 antibody with potential anticancer activity and activation of CD73POS B cells. |
In vitro | Mupadolimab induces increased expression of markers associated with B cell maturation and antigen presentation, transformation into plasma cells, as well as increased secretion of IgM and IgG[1]. |
In vivo | Mupadolimab (10 mg/kg; intraperitoneal injection; once daily for 15 days) stimulates antigen-specific humoral immunity in NSG-SGM3 mice infected with SARS-CoV-2[1]. |
Alias | CPI-006 |
Molecular Weight | 146.92 kDa |
Cas No. | 2451856-97-4 |
Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.